Indium-111-labeled B72.3 monoclonal antibody in the detection and staging of breast cancer

A phase I study

L. M. Lamki, A. U. Buzdar, S. E. Singletary, M. G. Rosenblum, V. Bhadkamkar, L. Esparza, D. A. Podoloff, A. Zukiwski, G. N. Hortobagyi, J. L. Murray

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Sixteen patients with primary breast cancer were studied with a pancarcinoma monoclonal antibody B72.3, an IgG1 molecule directed against tumor-associated glycoprotein (TAG-72) present in several tumors. Five millicuries of 111In was used to label 0.2 mg (six patients), or 2 mg (six patients), or 20 mg using the site-directed bifunctional DTPA method (at carbohydrate moiety). Digital, planar, and SPECT images were obtained at 2, 48, 72 and 96 hr when possible. HAMA levels were obtained before the Mab infusion and at 1, 3, and 6 wk postinfusion. Fourteen of 14 known primary breast lesions were detected by imaging (100% sensitivity). Two fibrocystic lesions were negative. Seven of 14 patients had lymph node metastases by histologic methods, but all were missed by radioimmunoscintigraphy. Tumor uptake of Mab ranged 0.00054%-0.0038% of the ID/g. The tumor-to-normal breast tissue ratio was 4.3 ± 0.91 (mean ± s.e.m.). Lymph nodes localization of 111In-B72.3 by tissue analysis was similar for tumor-bearing and normal nodes (0.0039 ± 0.0023 versus 0.0025 ± 0.0019). Pharmacokinetics revealed mean plasma half-life of 33.3-41.2 hr for the different doses. There was no statistical difference between any of the pharmacokinetic parameters of different doses. HAMA was positive only in 17% of the patients. The study suggests that this antibody has 100% sensitivity for primary breast cancers, but very poor detection rate of metastatic lesions in axillary lymph nodes; thus making it of questionable value in the initial staging process of this disease.

Original languageEnglish
Pages (from-to)1326-1332
Number of pages7
JournalJournal of Nuclear Medicine
Volume32
Issue number7
Publication statusPublished - 1991

Fingerprint

Indium
Monoclonal Antibodies
Breast Neoplasms
Lymph Nodes
Neoplasms
Breast
Pharmacokinetics
Radioimmunodetection
Pentetic Acid
Single-Photon Emission-Computed Tomography
Half-Life
Immunoglobulin G
Carbohydrates
B72.3 antibody
Neoplasm Metastasis
Antibodies

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Lamki, L. M., Buzdar, A. U., Singletary, S. E., Rosenblum, M. G., Bhadkamkar, V., Esparza, L., ... Murray, J. L. (1991). Indium-111-labeled B72.3 monoclonal antibody in the detection and staging of breast cancer: A phase I study. Journal of Nuclear Medicine, 32(7), 1326-1332.

Indium-111-labeled B72.3 monoclonal antibody in the detection and staging of breast cancer : A phase I study. / Lamki, L. M.; Buzdar, A. U.; Singletary, S. E.; Rosenblum, M. G.; Bhadkamkar, V.; Esparza, L.; Podoloff, D. A.; Zukiwski, A.; Hortobagyi, G. N.; Murray, J. L.

In: Journal of Nuclear Medicine, Vol. 32, No. 7, 1991, p. 1326-1332.

Research output: Contribution to journalArticle

Lamki, LM, Buzdar, AU, Singletary, SE, Rosenblum, MG, Bhadkamkar, V, Esparza, L, Podoloff, DA, Zukiwski, A, Hortobagyi, GN & Murray, JL 1991, 'Indium-111-labeled B72.3 monoclonal antibody in the detection and staging of breast cancer: A phase I study', Journal of Nuclear Medicine, vol. 32, no. 7, pp. 1326-1332.
Lamki LM, Buzdar AU, Singletary SE, Rosenblum MG, Bhadkamkar V, Esparza L et al. Indium-111-labeled B72.3 monoclonal antibody in the detection and staging of breast cancer: A phase I study. Journal of Nuclear Medicine. 1991;32(7):1326-1332.
Lamki, L. M. ; Buzdar, A. U. ; Singletary, S. E. ; Rosenblum, M. G. ; Bhadkamkar, V. ; Esparza, L. ; Podoloff, D. A. ; Zukiwski, A. ; Hortobagyi, G. N. ; Murray, J. L. / Indium-111-labeled B72.3 monoclonal antibody in the detection and staging of breast cancer : A phase I study. In: Journal of Nuclear Medicine. 1991 ; Vol. 32, No. 7. pp. 1326-1332.
@article{7f642c0704b746fb8319f7ef0bcb4803,
title = "Indium-111-labeled B72.3 monoclonal antibody in the detection and staging of breast cancer: A phase I study",
abstract = "Sixteen patients with primary breast cancer were studied with a pancarcinoma monoclonal antibody B72.3, an IgG1 molecule directed against tumor-associated glycoprotein (TAG-72) present in several tumors. Five millicuries of 111In was used to label 0.2 mg (six patients), or 2 mg (six patients), or 20 mg using the site-directed bifunctional DTPA method (at carbohydrate moiety). Digital, planar, and SPECT images were obtained at 2, 48, 72 and 96 hr when possible. HAMA levels were obtained before the Mab infusion and at 1, 3, and 6 wk postinfusion. Fourteen of 14 known primary breast lesions were detected by imaging (100{\%} sensitivity). Two fibrocystic lesions were negative. Seven of 14 patients had lymph node metastases by histologic methods, but all were missed by radioimmunoscintigraphy. Tumor uptake of Mab ranged 0.00054{\%}-0.0038{\%} of the ID/g. The tumor-to-normal breast tissue ratio was 4.3 ± 0.91 (mean ± s.e.m.). Lymph nodes localization of 111In-B72.3 by tissue analysis was similar for tumor-bearing and normal nodes (0.0039 ± 0.0023 versus 0.0025 ± 0.0019). Pharmacokinetics revealed mean plasma half-life of 33.3-41.2 hr for the different doses. There was no statistical difference between any of the pharmacokinetic parameters of different doses. HAMA was positive only in 17{\%} of the patients. The study suggests that this antibody has 100{\%} sensitivity for primary breast cancers, but very poor detection rate of metastatic lesions in axillary lymph nodes; thus making it of questionable value in the initial staging process of this disease.",
author = "Lamki, {L. M.} and Buzdar, {A. U.} and Singletary, {S. E.} and Rosenblum, {M. G.} and V. Bhadkamkar and L. Esparza and Podoloff, {D. A.} and A. Zukiwski and Hortobagyi, {G. N.} and Murray, {J. L.}",
year = "1991",
language = "English",
volume = "32",
pages = "1326--1332",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "7",

}

TY - JOUR

T1 - Indium-111-labeled B72.3 monoclonal antibody in the detection and staging of breast cancer

T2 - A phase I study

AU - Lamki, L. M.

AU - Buzdar, A. U.

AU - Singletary, S. E.

AU - Rosenblum, M. G.

AU - Bhadkamkar, V.

AU - Esparza, L.

AU - Podoloff, D. A.

AU - Zukiwski, A.

AU - Hortobagyi, G. N.

AU - Murray, J. L.

PY - 1991

Y1 - 1991

N2 - Sixteen patients with primary breast cancer were studied with a pancarcinoma monoclonal antibody B72.3, an IgG1 molecule directed against tumor-associated glycoprotein (TAG-72) present in several tumors. Five millicuries of 111In was used to label 0.2 mg (six patients), or 2 mg (six patients), or 20 mg using the site-directed bifunctional DTPA method (at carbohydrate moiety). Digital, planar, and SPECT images were obtained at 2, 48, 72 and 96 hr when possible. HAMA levels were obtained before the Mab infusion and at 1, 3, and 6 wk postinfusion. Fourteen of 14 known primary breast lesions were detected by imaging (100% sensitivity). Two fibrocystic lesions were negative. Seven of 14 patients had lymph node metastases by histologic methods, but all were missed by radioimmunoscintigraphy. Tumor uptake of Mab ranged 0.00054%-0.0038% of the ID/g. The tumor-to-normal breast tissue ratio was 4.3 ± 0.91 (mean ± s.e.m.). Lymph nodes localization of 111In-B72.3 by tissue analysis was similar for tumor-bearing and normal nodes (0.0039 ± 0.0023 versus 0.0025 ± 0.0019). Pharmacokinetics revealed mean plasma half-life of 33.3-41.2 hr for the different doses. There was no statistical difference between any of the pharmacokinetic parameters of different doses. HAMA was positive only in 17% of the patients. The study suggests that this antibody has 100% sensitivity for primary breast cancers, but very poor detection rate of metastatic lesions in axillary lymph nodes; thus making it of questionable value in the initial staging process of this disease.

AB - Sixteen patients with primary breast cancer were studied with a pancarcinoma monoclonal antibody B72.3, an IgG1 molecule directed against tumor-associated glycoprotein (TAG-72) present in several tumors. Five millicuries of 111In was used to label 0.2 mg (six patients), or 2 mg (six patients), or 20 mg using the site-directed bifunctional DTPA method (at carbohydrate moiety). Digital, planar, and SPECT images were obtained at 2, 48, 72 and 96 hr when possible. HAMA levels were obtained before the Mab infusion and at 1, 3, and 6 wk postinfusion. Fourteen of 14 known primary breast lesions were detected by imaging (100% sensitivity). Two fibrocystic lesions were negative. Seven of 14 patients had lymph node metastases by histologic methods, but all were missed by radioimmunoscintigraphy. Tumor uptake of Mab ranged 0.00054%-0.0038% of the ID/g. The tumor-to-normal breast tissue ratio was 4.3 ± 0.91 (mean ± s.e.m.). Lymph nodes localization of 111In-B72.3 by tissue analysis was similar for tumor-bearing and normal nodes (0.0039 ± 0.0023 versus 0.0025 ± 0.0019). Pharmacokinetics revealed mean plasma half-life of 33.3-41.2 hr for the different doses. There was no statistical difference between any of the pharmacokinetic parameters of different doses. HAMA was positive only in 17% of the patients. The study suggests that this antibody has 100% sensitivity for primary breast cancers, but very poor detection rate of metastatic lesions in axillary lymph nodes; thus making it of questionable value in the initial staging process of this disease.

UR - http://www.scopus.com/inward/record.url?scp=0025845955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025845955&partnerID=8YFLogxK

M3 - Article

VL - 32

SP - 1326

EP - 1332

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 7

ER -